The company’s lead drug candidate,.
The company’s lead drug candidate, oritavancin, is an intravenous antibiotic intended for treatment of drug-resistant bacterial infections. It has been tested against skin and “skin structure” infections as well as bacteremia, an infection of the blood, and is intended to supplant vancomycin, a generic antibiotic that is starting to lose potency against resistant bacterial strains..
Original text search at: venturebeat.com/tag/cointermune/